Blexten Dose for Post-Nasal Drip
Bilastine (Blexten) is dosed at 20 mg once daily in adults and adolescents ≥12 years, and 10 mg once daily in children aged 6 to <12 years for treating allergic rhinitis, which commonly presents with post-nasal drip. 1, 2
Dosing by Age Group
- Adults and adolescents ≥12 years: 20 mg once daily
- Children 6 to <12 years: 10 mg once daily
- Children 2 to <6 years: 10 mg once daily (though approval varies by region) 3
The pediatric 10 mg dose was specifically validated through pharmacokinetic studies showing equivalent systemic exposure to the adult 20 mg dose when adjusted for body weight, with median pediatric/adult ratios for AUC and Cmax of 0.93 and 0.91 respectively 2.
Clinical Context for Post-Nasal Drip
Post-nasal drip is a cardinal symptom of allergic rhinitis, and second-generation antihistamines like bilastine are recommended as first-line treatment 4. Bilastine has several advantages:
- Rapid onset: Therapeutic effect begins within hours of administration 1
- Non-sedating: Unlike first-generation antihistamines, bilastine shows minimal CNS penetration and no sedative properties at recommended doses 1, 5
- Once-daily dosing: Improves compliance
- No dose adjustments needed: Safe in renal/hepatic impairment and elderly patients 1
Important Caveats
The evidence provided shows bilastine is approved for allergic rhinoconjunctivitis and urticaria, not specifically for isolated post-nasal drip. If post-nasal drip is due to allergic rhinitis, bilastine is appropriate. However, if PND stems from non-allergic rhinitis, vasomotor rhinitis, or laryngopharyngeal reflux, intranasal corticosteroids may be more effective 4, 6.
The 2008 rhinitis guidelines emphasize that intranasal corticosteroids are the most effective medications for treating allergic rhinitis overall 4, though antihistamines remain first-line for mild-to-moderate symptoms. For isolated rhinorrhea or post-nasal drip without other allergic symptoms, consider intranasal anticholinergics (ipratropium bromide) as an alternative 4.
Safety Profile
Bilastine demonstrated excellent safety in pediatric trials, with treatment-emergent adverse events comparable to placebo (31.5% vs 32.5%) over 12 weeks 5. No clinically significant ECG changes, sedation scores, or laboratory abnormalities were observed 2, 5. This makes it particularly suitable for children over sedating antihistamines, which have been associated with serious adverse events including fatalities in young children 4.
Take bilastine on an empty stomach (1 hour before or 2 hours after food) as food can reduce absorption, though this is not explicitly stated in the provided evidence, it is standard for bilastine administration based on its pharmacokinetic profile.